Formycon Valuation Multiples

Formycon Overview

About Formycon

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Founded

2010

HQ

Employees

250

Website

formycon.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $74M

EBITDA: ($16M)

EV

$371M

Valuation Multiples

Multiples.vc

Start free trial

Formycon Financials

Formycon reported last 12-month revenue of $74M and negative EBITDA of ($16M).

In the same LTM period, Formycon generated $8M in gross profit, ($16M) in EBITDA losses, and had net loss of ($55M).

Formycon P&L

In the most recent fiscal year, Formycon reported revenue of $82M and EBITDA of ($5M).

Formycon expects next 12-month revenue of XXX and NTM EBITDA of XXX

Formycon Stock Performance

Formycon has current market cap of $391M, and enterprise value of $371M.

Formycon's stock price is $22.13.

Formycon Valuation Multiples

Formycon trades at 5.0x EV/Revenue multiple, and (23.6x) EV/EBITDA.

Formycon Financial Valuation Multiples

As of April 18, 2026, Formycon has market cap of $391M and EV of $371M.

Equity research analysts estimate Formycon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Formycon has a P/E ratio of (7.1x).

Formycon Margins & Growth Rates

Formycon's revenue in the last 12 month grew by 54%.

Formycon's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Formycon's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Formycon's rule of X is 133% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Formycon Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Formycon M&A Activity

Formycon acquired XXX companies to date.

Last acquisition by Formycon was on XXXXXXXX, XXXXX. Formycon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Formycon Investment Activity

Formycon invested in XXX companies to date.

Formycon made its latest investment on XXXXXXXX, XXXXX. Formycon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).